 OncoSec Medical Incorporated the Company or OncoSec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating the utility of OncoSecs next-generation product candidate, TAVOPLUS enhanced interleukin-12 or IL-12 plasmid, and its electroporation gene delivery system as a promising approach for patients with melanoma and other solid tumors. The data were selected for two late-breaking poster presentations at the American Association for Cancer AACR Virtual Annual Meeting II being held June 22-24, 2020. 